Stockscreener 앱 받기
0.764
8.29%
-0.0691
시간 외 거래:
.77
0.006
+0.79%
전일 마감가:
$0.8331
열려 있는:
$0.8057
하루 거래량:
1.11M
Relative Volume:
0.49
시가총액:
$123.63M
수익:
$400.57M
순이익/손실:
$9.21M
주가수익비율:
19.10
EPS:
0.04
순현금흐름:
$146.36M
1주 성능:
-6.78%
1개월 성능:
+6.53%
6개월 성능:
-67.35%
1년 성능:
-88.81%
1일 변동 폭
$0.7582
$0.8497
1주일 범위
$0.7582
$0.9481
52주 변동 폭
$0.5271
$6.935
아이언우드 제약 Stock (IRWD) Company Profile
명칭
Ironwood Pharmaceuticals Inc
전화
617-621-7722
주소
100 SUMMER STREET, SUITE 2300, BOSTON, MA
IRWD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IRWD
Ironwood Pharmaceuticals Inc
|
0.764 | 134.81M | 400.57M | 9.21M | 146.36M | 0.04 |
|
ZTS
Zoetis Inc
|
145.79 | 66.25B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.72 | 42.95B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.43 | 43.30B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.45 | 19.30B | 16.54B | -1.64B | 749.00M | -1.45 |
|
NBIX
Neurocrine Biosciences Inc
|
128.23 | 13.53B | 2.41B | 305.80M | 492.20M | 2.95 |
아이언우드 제약 Stock (IRWD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-15 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-04-15 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-04-14 | 다운그레이드 | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-09-09 | 개시 | Leerink Partners | Market Perform |
| 2024-08-08 | 다운그레이드 | CapitalOne | Overweight → Equal Weight |
| 2024-01-17 | 개시 | Craig Hallum | Buy |
| 2023-12-14 | 개시 | Wells Fargo | Overweight |
| 2023-11-09 | 개시 | Jefferies | Buy |
| 2023-09-28 | 개시 | JMP Securities | Mkt Outperform |
| 2022-09-02 | 개시 | CapitalOne | Overweight |
| 2022-04-22 | 개시 | Piper Sandler | Overweight |
| 2020-09-30 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-06-17 | 개시 | Northland Capital | Outperform |
| 2019-07-10 | 재개 | Credit Suisse | Neutral |
| 2019-03-27 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2019-02-25 | 업그레이드 | H.C. Wainwright | Sell → Neutral |
| 2019-01-24 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2018-11-07 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2018-11-07 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2018-07-23 | 개시 | H.C. Wainwright | Sell |
| 2018-05-09 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2018-01-05 | 다운그레이드 | BofA/Merrill | Buy → Underperform |
| 2017-12-06 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2017-07-21 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2017-05-03 | 개시 | Wells Fargo | Outperform |
| 2017-04-07 | 재확인 | Mizuho | Buy |
| 2017-02-22 | 재확인 | Barclays | Equal Weight |
| 2016-11-04 | 재확인 | Mizuho | Buy |
| 2016-10-24 | 재확인 | Wedbush | Neutral |
| 2016-10-10 | 재확인 | Mizuho | Buy |
| 2016-09-27 | 재확인 | WallachBeth | Hold |
모두보기
아이언우드 제약 주식(IRWD)의 최신 뉴스
How hedge fund analytics apply to Ironwood Pharmaceuticals Inc. stockAI Driven Buy Alert Trade Blueprint Released - metal.it
What makes Ironwood Pharmaceuticals Inc. stock price move sharplyCommunity Entry Consensus Trade Ideas Shared - metal.it
Ironwood Pharmaceuticals Inc. Recovery Likely Here’s What Data ShowsReal Time Alerts Based on AI Prediction Triggered - metal.it
Heatmap Data Shows High Activity in Ironwood Pharmaceuticals Inc. SectorAccurate Buy Point for Momentum Stocks Detected - metal.it
What are the latest earnings results for Ironwood Pharmaceuticals Inc.Achieve superior capital gains with smart trades - jammulinksnews.com
Is it the right time to buy Ironwood Pharmaceuticals Inc. stockOutstanding trading profits - jammulinksnews.com
What are Ironwood Pharmaceuticals Inc. company’s key revenue driversFree Stock Market Real-Time Monitoring - jammulinksnews.com
What catalysts could drive Ironwood Pharmaceuticals Inc. stock higher in 2025Maximize your investment portfolio’s performance - jammulinksnews.com
How strong is Ironwood Pharmaceuticals Inc. company’s balance sheetGet timely market insights for better trades - jammulinksnews.com
Is Ironwood Pharmaceuticals Inc. stock overvalued or undervaluedRecord-setting profit potential - jammulinksnews.com
Ironwood Pharmaceuticals Inc. Stock Analysis and ForecastAccelerated capital growth - PrintWeekIndia
Ironwood Pharmaceuticals Inc: Analyzing IRWD Stock Trends - investchronicle.com
What drives Ironwood Pharmaceuticals Inc. stock priceTriple-digit wealth increases - Autocar Professional
What analysts say about Ironwood Pharmaceuticals Inc. stockHigh-yield market plays - Autocar Professional
Is Ironwood Pharmaceuticals Inc. a good long term investmentRapid portfolio appreciation - jammulinksnews.com
How the Irritable Bowel Syndrome (IBS) Treatment Market Will - openPR.com
How Ironwood Pharmaceuticals Inc. stock performs during market volatilityTop Gaining Low Risk Assets - Newser
Why Ironwood Pharmaceuticals Inc. stock attracts strong analyst attentionHigh Confidence Trade Setups - Newser
Endometriosis Pain Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Organon, Ironwood Pharma, Mitsubishi Tanabe Pharma Corp, AbbVie/Neurocrine - The Globe and Mail
Endometriosis Pain Pipeline 2025: FDA Updates, Therapy Innovations, And Clinical Trial Landscape Analysis By Delveinsight Organon, Ironwood Pharma, Mitsubishi Tanabe Pharma Corp, Abbvie/Neurocrine - MenaFN
아이언우드 제약 (IRWD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.90%
0.85%
자본화:
|
볼륨(24시간):